Compare Carlyle Group Inc (CG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Zoetis Inc — how do they compare? Carlyle Group Inc trades at $48.3 (market cap $17.23B), while Zoetis Inc trades at $73.47 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Carlyle Group Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals.
| CG | ZTS | |
|---|---|---|
Market Cap | $17.23B | $31.14B |
Sector | Financials | Health |
52-Week High | $69.35 | $156.76 |
52-Week Low | $40.52 | $71.91 |
Dividend Yield | 2.9% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carlyle Group (CG) trades at $47.87, up 0.15% today, with a bullish technical signal and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat estimates, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility from $3.4B in 2024 to $3.2B in 2025. The stock is supported by strong institutional interest and dividend payments of $0.35 per share.
The outlook is positive with analyst buy ratings at 54%, but risks include declining net income margins and negative operating cash flows. Investment opportunity lies in valuation upside to the price target, though investors should monitor earnings consistency and macroeconomic impacts on asset management.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
